Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening

Cuiying Xie; Ancheng Gu; Muhammad Khan; Xiangcao Yao; Leping Chen; Jiali He; Fumiao Yuan; Ping Wang; Yufan Yang; Yerong Wei; Fang Tang; Hualong Su; Jiamin Chen; Jinxia Li; Bohong Cen; Zhongyuan Xu

doi:10.3389/fonc.2022.1105454

Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening

Front Oncol. 2023 Jan 6:12:1105454. doi: 10.3389/fonc.2022.1105454. eCollection 2022.

Authors

Cuiying Xie^{1

2}, Ancheng Gu^{1

2}, Muhammad Khan³, Xiangcao Yao^{1

2}, Leping Chen^{1

2}, Jiali He^{1

2}, Fumiao Yuan^{1

2}, Ping Wang^{1

2}, Yufan Yang^{1

2}, Yerong Wei^{1

2}, Fang Tang^{1

2}, Hualong Su^{1

2}, Jiamin Chen^{1

2}, Jinxia Li^{1

2}, Bohong Cen^{1

2

3}, Zhongyuan Xu^{1

2}

Affiliations

¹ Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
² National Medical Products Administration (NMPA) Key Laboratory for Research and Evaluation of Drug Metabolism and Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China.
³ Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China.

Abstract

Hepatocellular carcinoma is one of the malignancies worldwide with a high mortality rate and an increasing incidence. Molecular Targeted agents are its common first-line treatment. Organoid technology, as a cutting-edge technology, is gradually being applied in the development of therapeutic oncology. Organoid models can be used to perform sensitivity screening of targeted drugs to facilitate the development of innovative therapeutic agents for the treatment of hepatocellular carcinoma. The purpose of this review is to provide an overview of the opportunities and challenges of hepatocellular carcinoma organoids in targeted drug sensitivity testing as well as a future outlook.

Keywords: drug screening; hepatocellular carcinoma; organoids; targeted drugs; tumor microenvironment.

Publication types

Review